Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 05/29 04:00:00 pm
512.56 USD   +0.09%
05/27DJRetrophin Sells FDA Voucher to Sanofi
05/27DJRetrophin Sells FDA Voucher to Sanofi for $245 Million -- Update
05/27DJRetrophin Sells FDA Voucher To Sanofi For $245 Million
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2015 05/26/2015 05/27/2015 05/28/2015 05/29/2015 Date
513.88(c) 506.63(c) 515.37(c) 512.12(c) 512.56(c) Last
771 492 774 781 625 685 702 544 730 919 Volume
-0.41% -1.41% +1.73% -0.63% +0.09% Change
More quotes
Financials ($)
Sales 2015 3 704 M
EBIT 2015 1 433 M
Net income 2015 513 M
Finance 2015 1 112 M
Yield 2015 -
Sales 2016 4 471 M
EBIT 2016 1 951 M
Net income 2016 887 M
Finance 2016 2 995 M
Yield 2016 -
PER 2015 116,50
PER 2016 66,60
EV / Sales 2015 14,0x
EV / Sales 2016 11,2x
Capitalization 52 936 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
06/12Shareholder meeting
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
05/27DJRetrophin Sells FDA Voucher to Sanofi
05/27DJRetrophin Sells FDA Voucher to Sanofi for $245 Million -- Update
05/27DJRetrophin Sells FDA Voucher To Sanofi For $245 Million
05/21 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Results from Ph..
05/21DJSANOFI : Regeneron Seek US Approval for Rheumatoid Arthritis Drug
05/07 REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
05/07 REGENERON PHARMACEUTICALS : Results of Operations and Financial Condition, Finan..
05/07 REGENERON PHARMACEUTICALS : Reports First Quarter 2015 Financial and Operating R..
More news
Sector news : Pharmaceuticals - NEC
09:29a ASTRAZENECA : and MedImmune Present Positive Immuno-Oncology Combination Data at..
09:13a ASTRAZENECA : and MedImmune present positive immuno-oncology combination data at..
07:38a ROCHE BEARER SHARE : Collaborative group phase III study shows Roche’s Ava..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/27 Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs
05/26 Health Care Stocks For A Dividend Growth Portfolio - Part 1
05/26 FDA clears Boehringer Ingelheim's next generation COPD med
05/25 Best And Worst Performing S&P 500 Stocks Year-To-Date
05/22 What Is 'Smart Money' Shorting In This Psychotically Bullish Market


Comments 
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions